Trial Profile
Phase IV Multi-Center, Prospective, Interventional, Post-Marketing Study in Hemophilia B Patients in India Receiving RIXUBIS as On-demand or Prophylaxis Under Standard Clinical Practice
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Sep 2022
Price :
$35
*
At a glance
- Drugs Nonacog gamma (Primary)
- Indications Haemophilia B
- Focus Adverse reactions
- Sponsors Baxalta; Shire; Takeda
- 14 Jan 2022 Status changed from active, no longer recruiting to completed.
- 02 Jun 2021 Planned End Date changed from 21 Apr 2021 to 16 Dec 2021.
- 02 Jun 2021 Planned primary completion date changed from 21 Apr 2021 to 16 Dec 2021.